Is Wall Road Bullish or Bearish?

Amgen Inc. (AMGN) is a number one biotechnology firm headquartered in Thousand Oaks, California. It specializes within the discovery, growth, manufacturing, and supply of modern human therapeutics, significantly biologics that concentrate on critical sicknesses similar to most cancers, heart problems, irritation, and bone issues. Amgen pioneered recombinant DNA expertise to advance affected person care globally. The corporate has a market capitalization of $184.10 billion.

The inventory has been dealing with strong investor sentiment. Over the previous 52 weeks, Amgen’s inventory has gained 20.4%, whereas over the previous six months, it has risen 13.4%. The corporate’s shares reached a 52-week excessive of $353.25 on Jan. 27, however are down 3.2% from that degree.

Then again, the broader S&P 500 Index ($SPX) has gained 14.3% and 9.1% over the identical durations, respectively, indicating that the inventory has outperformed the broader market. Subsequent, we examine the inventory with its personal sector. The State Road Well being Care Choose Sector SPDR ETF (XLV) has elevated 5% over the previous 52 weeks and 15.3% over the previous six months. Subsequently, whereas the inventory has outperformed its sector over the previous 12 months, it has underperformed over the previous six months.

Amgen is taking some strategic strides to bolster its enterprise. Fitch Scores acknowledged the corporate’s improved monetary construction and debt compensation after the acquisition of Horizon Therapeutics by elevating its long-term issuer default score from “BBB” to “BBB+.” The corporate additionally acquired a U.Ok.-based biotech agency, Darkish Blue Therapeutics, which is predicted to bolster Amgen’s oncology portfolio.

The corporate’s third-quarter outcomes have been higher than what analysts had anticipated. For the fourth quarter of 2025 (to be reported on Feb. 3, after the market closes), Wall Road analysts count on Amgen’s EPS to say no 10.6% YOY to $4.75 on a diluted foundation. Nevertheless, EPS is predicted to extend 7.3% yearly to $21.29 for fiscal 2025, adopted by a 2.6% enchancment to $21.85 in fiscal 2026. The corporate has a strong historical past of surpassing consensus estimates, topping them in all 4 trailing quarters.

Among the many 33 Wall Road analysts masking Amgen’s inventory, the consensus is a “Reasonable Purchase.” That’s primarily based on 14 “Sturdy Purchase” scores, two “Reasonable Buys,” 14 “Holds,” one “Reasonable Promote,” and two “Sturdy Sells.” The scores configuration has turn into extra bullish than two months in the past, with 14 “Sturdy Purchase” scores, up from 13.

Just lately, analysts at Bernstein downgraded Amgen’s inventory from “Outperform” to “Market Carry out,” citing that 2026 may very well be a “ready 12 months” for the inventory, as its weight problems candidate MariTide awaits its first Part 3 trial information and its ldl cholesterol drug Repatha faces competitors from Merck’s (MRK) oral PCSK9 inhibitor, Enlicitide.

Amgen’s imply worth goal of $336.29 signifies a 1.6% draw back over present market costs. Nevertheless, the Road-high worth goal of $425 implies a possible upside of 24.3%.

On the date of publication, Anushka Dutta didn’t have (both immediately or not directly) positions in any of the securities talked about on this article. All info and information on this article is solely for informational functions. This text was initially printed on Barchart.com